Intra-Cellular Therapies Inc.
ITCI
ITCI was delisted on the 1st of April, 2025.
35 hedge funds and large institutions have $201M invested in Intra-Cellular Therapies Inc. in 2014 Q1 according to their latest regulatory filings, with 35 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$79.1M |
| 2 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$19.2M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
+$18.1M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$15.2M |
| 5 |
VAM
Visium Asset Management
New York
|
+$12.6M |
Top Sellers
ITCI Hedge Fund Activity: Q1 2014 in Review
35 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q1 2014, worth a combined $201M.
Buyers outnumbered sellers: 35 funds opened new ITCI positions and 0 closed out — a net gain of 35 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $79.1M.
- 35 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q1 2014, up from 0 in Q4 2013.
- Funds reported $201M of Intra-Cellular Therapies Inc. stock for Q1 2014.
- 35 funds opened new Intra-Cellular Therapies Inc. positions in Q1 2014 and 0 closed out, a net change of +35 holders.
- The largest Intra-Cellular Therapies Inc. buyer in Q1 2014 was Fidelity Investments, an estimated $79.1M added.
Based on aggregated 13F filings for Q1 2014.